A Retrospective Multicenter Study for the Assessment of Effectiveness of Secukinumab as Assessed by Psoriasis Area and Severity Index With Subcutaneous Administration in Adult Patients With Moderate to Severe Plaque Psoriasis in Turkish Population
Latest Information Update: 04 May 2022
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 04 May 2022 New trial record